Q2 2020 · —
Revenue—
Net Income$2.26M$2.26M no prior Q2 2019 on fileN/M vs Q1 2020
EPS Diluted$0.22$0.22 no prior Q2 2019 on fileN/M vs Q1 2020
Operating Income-$5,065,000—
Operating Cash Flowderived-$4,295,000—
Free Cash Flowderived-$4,340,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q2 2019 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR